oxaliplatin / Generic mfg. |
| Completed | 2b | 198 | US, Europe, RoW | Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin), Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin) | Bayer, Amgen | Metastatic Colorectal Cancer | 01/11 | 02/12 | | |
|
| Terminated | 2b | 191 | Japan, US, Europe | sunitinib, Sutent, SU011248, mFOLFOX6, bevacizumab, Avastin | Pfizer | Colorectal Neoplasms | 07/11 | 07/11 | | |
NCT00016198: Fluorouracil and Leucovorin With or Without Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | FOLFOX regimen, fluorouracil, leucovorin calcium, oxaliplatin | Prologue Research International | Colorectal Cancer | 04/03 | 12/10 | | |
NCT00017082: Oxaliplatin in Treating Patients With Recurrent Metastatic Colorectal Cancer |
|
|
| Completed | 2 | | US | oxaliplatin | Prologue Research International | Colorectal Cancer | 06/03 | 12/10 | | |
NCT00044343: GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin |
|
|
| Completed | 2 | 80 | US, Canada | lapatinib | GlaxoSmithKline | Colorectal Cancer | 10/03 | 10/03 | | |
NCT00065117: Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 180 | US | ZD6126, Placebo, 5-fluorouracil, leucovorin, oxaliplatin | AstraZeneca | Colorectal Neoplasms, Metastases, Neoplasm | 02/04 | 02/04 | | |
NCT00077987: Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments. |
|
|
| Completed | 2 | 84 | NA | SU011248 | Pfizer | Colorectal Neoplasms | | 04/05 | | |
NCT00399750: TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 373 | US | oxaliplatin, fluoropyrimidine, bevacizumab | Sanofi | Colorectal Cancer | | 06/05 | | |
NCT00120172: Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 40 | US | oxaliplatin, capecitabine, bevacizumab | Geriatric Oncology Consortium, Sanofi | Colorectal Cancer, Neoplasm Metastasis | | 06/06 | | |
NCT00123851: Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 32 | US | Tarceva (OSI-774), Capecitabine, Oxaliplatin | Dana-Farber Cancer Institute, Sanofi-Synthelabo, OSI Pharmaceuticals, Hoffmann-La Roche, Genentech, Inc., Massachusetts General Hospital, Beth Israel Deaconess Medical Center | Colorectal Cancer, Neoplasm Metastasis | 08/06 | 08/06 | | |
NCT00254137: Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 92 | Europe | capecitabine, irinotecan, oxaliplatin, cetuximab | Ludwig-Maximilians - University of Munich, Merck Sharp & Dohme LLC, Sanofi, Pfizer, Hoffmann-La Roche | Metastatic Colorectal Cancer | | 11/06 | | |
PROCTFUL, NCT00263029: Preoperative Radiotherapy/ Oxaliplatin/ Capecitabine Treatment For Unresectable Locally-advanced Rectal Cancer |
|
|
| Completed | 2 | 18 | RoW | Oxaliplatin, Capecitabine, Radiotherapy | Sanofi | Rectal Neoplasms | 03/07 | | | |
NCT00083616: Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
|
|
| Completed | 2 | 185 | US | Panitumumab, ABX-EGF, Vectibix | Amgen | Colorectal Cancer, Metastatic Cancer | 05/07 | 12/08 | | |
NCT00346099: Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum |
|
|
| Withdrawn | 2 | 0 | US | Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation | NSABP Foundation Inc, Amgen | Rectal Cancer, Neoplasm Metastasis | | 05/07 | | |
NCT00215982: Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 24 | US | capecitabine, XELODA™, Oxaliplatin, E LOXATIN™, Irinotecan, CAMPTOSAR™ | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Colorectal Cancer | 07/07 | 07/07 | | |
NCT00192075: A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 84 | US | Gemcitabine, Gemzar, avastin, 5FU/folinic acid, oxaliplatin | Eli Lilly and Company | Colorectal Cancer | | 11/07 | | |
NCT00174616: CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision |
|
|
| Completed | 2 | 87 | Europe | Oxaliplatin, capecitabine, radiotherapy | Sanofi | Rectal Neoplasms | 11/07 | 11/07 | | |
| Completed | 2 | 215 | Canada, Europe | AZD2171, cediranib, RECENTIN™, 5-fluorouracil, 5-FU, Leucovorin, Oxaliplatin, Eloxatin®, Bevacizumab, Avastin® | AstraZeneca | Colorectal Cancer | 11/07 | 10/09 | | |
NCT00454116 / 2006-005023-42: A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients |
|
|
| Completed | 2 | 106 | US, Europe, RoW | Vandetanib, ZD6474, ZACTIMA™, FOLFIRI | Genzyme, a Sanofi Company | Colorectal Cancer | 03/08 | 11/09 | | |
NCT00500292 / 2006-005022-23: A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer |
|
|
| Completed | 2 | 109 | Europe, RoW | Vandetanib, AZ6474, ZACTIMA™, SAR390530, FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid | Genzyme, a Sanofi Company | Colorectal, Cancer | 03/08 | 11/16 | | |
NCT00408772: Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | bevacizumab, capecitabine, oxaliplatin, conventional surgery, neoadjuvant therapy, radiofrequency ablation | University of California, Davis, Sanofi | Colorectal Cancer, Metastatic Cancer | 04/08 | 04/08 | | |
NCT00345696 / 2005-006171-12: 1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR. |
|
|
| Completed | 2 | 32 | Europe | Bevacizumab, Avastin, Capecitabine, Xeloda, Oxaliplatine, Eloxatin | Unidad Integral de Investigación en Oncología S.L., Hoffmann-La Roche | Metastatic Colorectal Cancer | 10/08 | 01/11 | | |
| Completed | 2 | 136 | Europe | FOLFOX-4+cetuximab, FOLFOX-4 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Colorectal Cancer | 02/09 | 02/09 | | |
NCT00419159 / 2006-003255-20: Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy |
|
|
| Completed | 2 | 199 | US | Everolimus (RAD001), Afinitor, Zortress, Certican | Novartis Pharmaceuticals | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00642603: A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 41 | US | capecitabine [Xeloda], bevacizumab [Avastin], oxaliplatin, irinotecan | Hoffmann-La Roche | Colorectal Cancer | 03/09 | 03/09 | | |
NCT00118755: A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 435 | US | capecitabine, Oxaliplatin, bevacizumab | Hoffmann-La Roche | Colorectal Cancer | 04/09 | | | |
NCT00531115 / 2006-007062-11: Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer. |
|
|
| Terminated | 2 | 28 | Europe | cetuximab 5mg/ml | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 04/09 | 04/09 | | |
XELOX-A-DVS, NCT00159432: Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer |
|
|
| Completed | 2 | 63 | US | Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Capecitabine, Xeloda | University of Southern California, Hoffmann-La Roche, Genentech, Inc. | Colorectal Cancer | 06/09 | 03/13 | | |
|
MK-7454-003, NCT00551213: A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, ) |
|
|
| Completed | 2 | 67 | NA | Robatumumab, Irinotecan, Cetuximab, Capecitabine, FOLFOX, CAPEOX/XELOX, FOLFIRI | Merck Sharp & Dohme LLC | Colorectal Cancer | 06/09 | 06/09 | | |
NCT00327119: Phase 2 Study of ABX-EGF (Panitumumab) in Japanese Subjects With M-colorectal Cancer |
|
|
| Completed | 2 | 50 | Japan | ABX-EGF (panitumumab) | Amgen | Metastatic Colorectal Cancer | | | | |
| Completed | 2 | 44 | Europe | IMC-11F8 (necitumumab), Necitumumab, IMC-11F8, LY3012211, Portrazza®, Oxaliplatin, Folinic acid (FA), 5-FU | Eli Lilly and Company | Metastatic Colorectal Cancer | 01/10 | 10/10 | | |
NCT00601198: A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer |
|
|
| Terminated | 2 | 4 | US | Amifostine, Flurouracil (5-FU), Leucovorin calcium (LV), Oxaliplatin, Bevacizumab | University of Cincinnati, MedImmune LLC, AstraZeneca | Colorectal Cancer | 01/10 | 01/10 | | |
NCT01135498 / 2005-004662-16: A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer. |
|
|
| Completed | 2 | 90 | Europe | bevacizumab [Avastin], eloxatin, capecitabine [Xeloda], erlotinib [Tarceva] | Hoffmann-La Roche | Colorectal Cancer | 04/10 | 04/10 | | |
NCT01159171 / 2005-001012-41: A Study of Avastin (Bevacizumab) and Oxaliplatin Plus Xeloda (Capecitabine) in Patients With Advanced Colorectal Cancer. |
|
|
| Completed | 2 | 50 | Europe | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 07/10 | 07/10 | | |
NCT00421824 / 2005-005149-20: Study of Neoadjuvant Chemotherapeutic Treatment (XELOX) Followed by Chemoradiotherapy (XELOX/RT) and Surgery Versus Chemoradiotherapy Followed by Surgery and Chemotherapy in Patients With High Risk Rectal Cancer |
|
|
| Completed | 2 | 108 | Europe | Oxaliplatin, capecitabine, Radiotherapy | Sanofi | Rectal Neoplasms | 11/10 | 11/10 | | |
NCT01022541 / 2005-004505-29: Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer |
|
|
| Completed | 2 | 47 | Europe | Capecitabine, Xeloda, Oxaliplatin, Eloxatin, Bevacizumab, Avastin, Liver metastasectomy | Royal Marsden NHS Foundation Trust, Roche Pharma AG | Metastatic Colorectal Cancer | 12/10 | 02/15 | | |
|
|
NCT00636610: A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 199 | NA | Vismodegib 150 mg, GDC-0449, Erivedge, Placebo to vismodegib, Bevacizumab, Modified FOLFOX, FOLFIRI | Genentech, Inc. | Metastatic Colorectal Cancer | 12/10 | 12/10 | | |
HEARTO, NCT01348412: Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure |
|
|
| Completed | 2 | 31 | Europe | oxaliplatin, raltitrexed, other intravenous chemotherapy drugs | Centre Georges Francois Leclerc, National Cancer Institute, France, Hospira, now a wholly owned subsidiary of Pfizer | Colorectal Cancer, Liver Metastases | 12/10 | 04/18 | | |
NCT00615056 / 2007-006283-30: A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen |
|
|
| Completed | 2 | 171 | Japan, US, Canada, Europe, RoW | Bevacizumab (avastin), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib), FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU]), FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU]) | Pfizer | Colorectal Neoplasms | 03/11 | 04/12 | | |
|
|
APRIORI, NCT01126866: Curative Resectability of Not Optimally Resectable Liver and/or Lung Metastases From Colorectal Carcinoma (CRC) Under Intensified Chemotherapy |
|
|
| Terminated | 2 | 35 | Europe | intensified chemotherapy (FOLFOXIRI/Bevacizumab) | National Center for Tumor Diseases, Heidelberg, Roche Pharma AG, Pfizer | Colorectal Carcinoma | 03/11 | 06/11 | | |
| Completed | 2 | 268 | Europe, RoW | aflibercept, ZALTRAP™, AVE0005, oxaliplatin, 5-FU, Folinic Acid | Sanofi | Colorectal Neoplasms, Neoplasm Metastasis | 04/11 | 01/12 | | |
|
| Completed | 2 | 48 | Canada, Europe | IMC-1121B (ramucirumab), ramucirumab, LY3009806, Oxaliplatin, Folinic acid, 5-FU | Eli Lilly and Company | Colorectal Carcinoma | 04/11 | 08/11 | | |
|
NCT00700570: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 45 | RoW | bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 11/11 | 11/11 | | |
| Terminated | 2 | 9 | Europe | Oxaliplatin, Capecitabine, Panitumumab, Oxaliplatin, Capecitabine | AIO-Studien-gGmbH, iOMEDICO AG | Colorectal Neoplasms | 11/11 | 03/12 | | |
NCT00642746: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) |
|
|
| Terminated | 2 | 16 | US | Erlotinib, Tarceva, Fluorouracil, Leucovorin, Oxaliplatin, Irinotecan | OHSU Knight Cancer Institute, Genentech, Inc., OSI Pharmaceuticals | Metastatic Colorectal Cancer | 12/11 | 12/11 | | |
NCT01077739 / 2009-012090-36: A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin |
|
|
| Completed | 2 | 75 | Europe | fluorouracil (5FU), leucovorin, bevacizumab [Avastin], capecitabine [Xeloda], oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 01/12 | 01/12 | | |
NCT00177307: Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer |
|
|
| Completed | 2 | 40 | US | Bevacizumab, Capecitabine 2500 mg/m2/d in two divided doses, (May be 2000 or 3000 mg/m2/d after interim analysis) Days 1-8, every 2 weeks Until disease progression or unacceptable toxicity, Oxaliplatin 85 mg/m2 IV q 2 weekly Until disease progression, unacceptable toxicity,, or Grade 3 neuropathy or cumulative dose of 1200 mg/m2, Capecitabine, Oxaliplatin | University of Pittsburgh, Genentech, Inc. | Cancer | 02/12 | 02/12 | | |
| Withdrawn | 2 | 0 | Canada | irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab | Ottawa Hospital Research Institute, Hoffmann-La Roche, Sanofi | Metastatic Colorectal Cancer | 02/12 | 02/12 | | |
NCT00721916: Randomized Phase II Study of SOL for Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 107 | Japan | SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin), mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin) | Taiho Pharmaceutical Co., Ltd., Yakult Honsha Co., LTD | Colorectal Cancer | 03/12 | 05/12 | | |
| Completed | 2 | 54 | US, Europe, RoW | Regorafenib (Stivarga, BAY73-4506), Oxaliplatin, Folinic acid, 5-FU (mFOLFOX6) | Bayer | Colorectal Neoplasms | 03/12 | 06/14 | | |
|
NCT00677144: Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer |
|
|
| Completed | 2 | 88 | RoW | OS (oxalipaltin+S-1), Eloxatin, TS-1, XELOX (oxalipaltin+capecitabine), Xeloda | Hallym University Medical Center, Sanofi | Colorectal Neoplasm | 04/12 | 04/12 | | |
NCT00707889 / 2007-007081-38: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer |
|
|
| Completed | 2 | 159 | US, Canada, Europe, RoW | ABT-869, bevacizumab, oxaliplatin, mFOLFOX6 regimen, folinic acid, fluorouracil | AbbVie (prior sponsor, Abbott), Genentech, Inc. | Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 05/12 | 05/12 | | |
|
|
| Completed | 2 | 171 | US, Europe, RoW | CT-011, FOLFOX | Medivation, Inc. | Metastatic Colorectal Cancer | 05/12 | 03/13 | | |
|
| Withdrawn | 2 | 0 | Canada | OXALIPLATIN (SR96669), 5-FLUOROURACIL (5-FU), LEUCOVORIN (LV), BEVACIZUMAB | Sanofi | Colorectal Neoplasms | 05/12 | 05/12 | | |
NCT01175291: FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | MK-0646, oxaliplatin, leucovorin, 5-FU, Fluorouracil, bevacizumab, Placebo, 5-Fluorouracil | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 07/12 | 07/12 | | |
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
| Completed | 2 | 47 | Europe | Cetuximab, Erbitux, Irinotecan, Camptosar, Oxaliplatin, Eloxatin, UFT, Tegafur, Uracil | The Christie NHS Foundation Trust, Merck Sharp & Dohme LLC | Metastatic Colorectal Cancer | 05/13 | 05/13 | | |
|
| Completed | 2 | 76 | US, Europe | Panitumumab, Vectibix, Ganitumab, AMG 479, Irinotecan | Amgen | Metastatic Colorectal Cancer | 07/13 | 07/13 | | |
| Completed | 2 | 25 | Europe | preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine, Xeloda (capecitabine), Avastin (bevacizumab), Oxaliplatin | Austrian Breast & Colorectal Cancer Study Group, Hoffmann-La Roche | Rectal Cancer | 08/13 | 08/13 | | |
NCT01478594 / 2011-003502-24: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy |
|
|
| Completed | 2 | 265 | US, Canada, Europe, RoW | Tivozanib, AV951, ASP4130, Bevacizumab, Avastin, mFOLFOX6 | AVEO Pharmaceuticals, Inc. | Colorectal Cancer | 09/13 | 01/15 | | |
|
|
|
|
|
|
|
|
| Completed | 2 | 80 | Europe | 5-FU, Irinotecan, Leucovorin, Oxaliplatin, bevacizumab [Avastin] | Hoffmann-La Roche | Colorectal Cancer | 10/13 | 10/13 | | |
|
SETICC, NCT01071655 / 2009-012562-31: Selecting Treatment in Colorectal Cancer:Capecitabine or 5-fluorouracil Selection to be Combined With Oxaliplatin or Irinotecan as First-line Chemotherapy in Advanced Colorectal Cancer |
|
|
| Completed | 2 | 195 | Europe | BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX, BVZ+XELOX | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Hoffmann-La Roche | Colorectal Cancer | 11/13 | 11/13 | | |
NCT00959647: A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study |
|
|
| Completed | 2 | 19 | US | Vismodegib, Erivedge, GDC-0449, RO5450815, FOLFOX, FOLFIRI, Bevacizumab, Avastin | Genentech, Inc. | Ovarian Cancer, Basal Cell Carcinoma, Metastatic Colorectal Cancer | 01/14 | 01/14 | | |
| Completed | 2 | 97 | Europe | 5-FU, bevacizumab [Avastin], irinotecan, leucovorin, oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 02/14 | 02/14 | | |
|
|
NCT01399684 / 2011-001867-28: A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 127 | US, Europe, RoW | 5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo | Genentech, Inc. | Metastatic Colorectal Cancer | 02/14 | 02/14 | | |
NCT01226719: FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only |
|
|
| Completed | 2 | 15 | US | Panitumumab, Combined Modality Treatment, Oxaliplatin, Irinotecan, Leucovorin, 5-Fluorouracil | SCRI Development Innovations, LLC, Amgen | Colorectal Cancer | 03/14 | 03/14 | | |
|
NCT01378143: Using OCZ103-OS in Patients With Unresectable and Locally Recurrent or Metastatic Colorectal Cancer Undergoing Standard Chemotherapy |
|
|
| Completed | 2 | 53 | Canada | OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI | Oncozyme Pharma Inc. | Colorectal Cancer | 03/14 | 07/14 | | |
APEC-Study, NCT00778830: Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 289 | RoW | Cetuximab, Erbitux, FOLFIRI, FOLFOX | Merck KGaA, Darmstadt, Germany, Merck Pte. Ltd., Singapore | Metastatic Colorectal Cancer | 04/14 | 04/14 | | |
|
|
|
|
|
| Completed | 2 | 77 | Europe | 5-Fluorouracil (5-FU), Bevacizumab, Avastin, Levofolinic acid, Oxaliplatin | Hoffmann-La Roche | Colorectal Cancer | 05/14 | 05/16 | | |
NCT00165854 / 2004-002597-33: Study of E7070 Combined With Capecitabine to Determine Efficacy and Recommended Dose of Combination in Patients With Metastatic Colorectal Cancer |
|
|
| Completed | 2 | 46 | Europe | E7070 | Eisai Limited | Colorectal Cancer (CRC) | | | | |
| Terminated | 2 | 266 | US, Europe, RoW | Simtuzumab, SIM; GS-6624, Placebo to match SIM, Leucovorin, Folinic acid, Irinotecan, Fluorouracil | Gilead Sciences | Colorectal Cancer | 10/14 | 02/15 | | |
| Completed | 2 | 80 | Europe | Panitumumab+FOLFOX-4, Panitumumab+FOLFIRI | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Amgen | Colorectal Cancer | 03/15 | 03/15 | | |
|
|
|
|
MAVERICC, NCT01374425 / 2011-004755-39: Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC) |
|
|
| Completed | 2 | 376 | US, Canada, Europe | 5-Fluorouracil, Bevacizumab, Avastin, Irinotecan, Leucovorin, Oxaliplatin, Capecitabine | Genentech, Inc. | Colorectal Cancer | 05/15 | 07/15 | | |
|
|
|
NCT01882868: A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan |
|
|
| Completed | 2 | 62 | Japan | Aflibercept, AVE0005, Levofolinate, Irinotecan, 5-FU | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 08/15 | 08/15 | | |
NCT01749956: 5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer |
|
|
| Completed | 2 | 39 | US | Radiation, Aflibercept, Eylea, Zaltrap, Surgery, FOLFOX6, Leucovorin (Folinic Acid), 5-Fluorouracil (5-FU; Efudex), Oxaliplatin (Eloxatin) | SCRI Development Innovations, LLC, Sanofi | Rectal Cancer | 09/15 | 09/15 | | |
NCT02046538: Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | Leucovorin, Wellcovorin, Oxaliplatin, Eloxatin, 5-FU, Adrucil, fluorouracil, Irinotecan, Camptosar | Weill Medical College of Cornell University, Sanofi | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 02/16 | 02/18 | | |
PREVIUM, NCT02175654 / 2014-000703-26: Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab |
|
|
| Terminated | 2 | 15 | Europe | Regorafenib | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Bayer | Colorectal Neoplasms, Metastatic Disease | 02/16 | 02/16 | | |
| Completed | 2 | 186 | US, Europe, RoW | PledOx (2 µmol/kg), Calmangafodipir, PledOx (5 µmol/kg), PledOx (10 µmol/kg), Placebo (0,9% NaCl), Sodium chloride | Egetis Therapeutics, Pharma Consulting Group AB | Advanced Metastatic (Stage IV) Colorectal Cancer | 03/16 | 12/16 | | |
STEAM, NCT01765582: Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer |
|
|
| Terminated | 2 | 280 | US | 5-fluorouracil, bevacizumab, Avastin, capecitabine, Xeloda, irinotecan, folinic acid, leucovorin, oxaliplatin | Hoffmann-La Roche | Colorectal Neoplasms | 03/16 | 03/16 | | |
|
|
| Completed | 2 | 91 | Europe | Bevacizumab, Avastin, Oxaliplatin, Folinic Acid, 5-fluorouracil, Preoperative Radiotherapy, Surgery | Hoffmann-La Roche | Rectal Cancer | 03/16 | 03/16 | | |
|
NCT01889680: Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | 5-FU, 5-fluorouracil, LV, leucovorin, ziv-aflibercept, mFOLFOX6, 5-FU plus leucovorin plus oxaliplatin | NSABP Foundation Inc, Sanofi | Colorectal Cancer, Metastatic Colorectal Cancer | 05/16 | 05/18 | | |
NCT02085005: Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | RoW | Capecitabine, Aflibercept AVE0005, Oxaliplatin SR96669 | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 08/16 | 08/16 | | |
| Completed | 2 | 250 | Europe | Oxaliplatin, 5FU/LV, Bevacizumab, Bevacizumab, Oxaliplatin, I-LV, 5-FU, 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan, Irinotecan | Martin-Luther-Universität Halle-Wittenberg, Roche Pharma AG | Metastatic Colorectal Cancer | 09/16 | 08/18 | | |
| Terminated | 2 | 44 | Europe | FOLFOX6, Chemotherapy, Bevacizumab, Avastin, Panitumumab, Vectibix, Surgery | European Organisation for Research and Treatment of Cancer - EORTC, Amgen, Roche Pharma AG | Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer | 09/16 | 09/16 | | |
|
NCT02079220: A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 2 | 0 | US | Arm A, Xeloda, ELOXATIN, ZALTRAP, Arm B | James J Lee, Sanofi | Metastatic Colorectal Cancer | 03/18 | 03/18 | | |
VISNU-2, NCT01640444 / 2012-000840-90: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) |
|
|
| Completed | 2 | 240 | Europe | FOLFIRI + bevacizumab, FOLFIRI + cetuximab | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Roche Pharma AG | Colorectal Cancer Metastatic | 11/18 | 11/18 | | |
NCT00625651: Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer |
|
|
| Completed | 1b/2 | 202 | US | Placebo, AMG 655, Modified FOLFOX6, mFOLFOX6, Bevacizumab | Amgen | Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer | 08/10 | 09/11 | | |
NCT00403624: Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer |
|
|
| Completed | 1/2 | 38 | Europe | OXALIPLATIN | Sanofi | Rectal Neoplasms | 11/05 | 11/05 | | |
| Terminated | 1/2 | 46 | Europe | Oxaliplatin | Sanofi | Rectal Neoplasms | 06/06 | | | |
CORGI, NCT01016639: Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer |
|
|
| Completed | 1/2 | 106 | Europe | oxaliplatin, capecitabine, radiotherapy | Lund University Hospital, Roche Pharma AG, Sanofi-Synthelabo | Stomach Cancer, Gall Bladder Cancer, Bile Ductus Cancer, Pancreas Cancer, Colorectal Cancer | 07/07 | 07/09 | | |
NCT00226941: A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer |
|
|
| Terminated | 1/2 | 23 | US | Cetuximab, Erbitux, C225, IMC-C225, Oxaliplatin, Eloxatin, Capecitabine, Xeloda, Radiotherapy, XRT, Diphenhydramine hydrochloride (HCl), Benadryl, Unisom, Sominex | George Albert Fisher, Bristol-Myers Squibb | Rectal Cancer, Colo-rectal Cancer | 03/08 | 02/09 | | |
NCT00345761: Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer |
|
|
| Completed | 1/2 | 64 | Japan | Bevacizumab, Oxaliplatin, Capecitabine | Chugai Pharmaceutical, Yakult Honsha Co., LTD | Colorectal Cancer | 10/08 | 07/10 | | |
NCT00536809: Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer |
|
|
| Completed | 1/2 | 12 | US | lapatinib, oxaliplatin, capecitabine | GlaxoSmithKline | Neoplasms, Colorectal | 10/08 | 10/08 | | |
NCT00494221: A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX |
|
|
| Completed | 1/2 | 172 | Japan | AZD2171, cediranib, RECENTIN™, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin), Eloxatin®, 5-FU, Leucovorin, Placebo Cediranib | AstraZeneca | Metastatic Colorectal Cancer | 10/09 | 08/12 | | |
|
| Completed | 1/2 | 51 | Europe | Oxaliplatin, Capecitabine, Bevacizumab, Imatinib, Xeloda, Avastin, Imatinib, Eloxatin | University of Cologne, Roche Pharma AG, Novartis, Sanofi | Stage IV Colorectal Cancer | 08/10 | 12/12 | | |
|
IMA910-101, NCT00785122 / 2007-005666-12: IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy |
|
|
| Completed | 1/2 | 92 | Europe, RoW | Endoxana, Leukine, IMA910, Endoxana (Cyclophosphamide), Aldara (Imiquimod), IMA910, GM-CSF, Endoxana, Leukine, IMA910, Aldara | Immatics Biotechnologies GmbH | Colorectal Carcinoma | 01/11 | 05/13 | | |
NCT00809796: A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment |
|
|
| Completed | 1/2 | 15 | Canada | pentamidine | Oncozyme Pharma Inc. | Colorectal Cancer | 05/11 | 06/11 | | |
NCT00819754: A Phase I/II Study of IXO With Bevacizumab in Patients With Metastatic Colorectal Cancer |
|
|
| Terminated | 1/2 | 23 | Canada | IXO regimen + bevacizumab, irinotecan - Camptosar, capecitabine - Xeloda, Oxaliplatin - Eloxatin, bevacizumab - Avastin | Ottawa Hospital Research Institute, Hoffmann-La Roche, Pfizer, Sanofi, Ottawa Regional Cancer Foundation | Metastatic Colorectal Cancer | 02/12 | 05/12 | | |
|
NCT01955629 / 2013-000858-22: Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient |
|
|
| Terminated | 1/2 | 4 | Europe | Aflibercept AVE0005, Zaltrap, Oxaliplatin, Eloxatin, SR96669, Capecitabine | Sanofi, Regeneron Pharmaceuticals | Colorectal Cancer Metastatic | 03/15 | 03/15 | | |
NCT01047293: RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma |
|
|
| Completed | 1/2 | 47 | US | RAD001, everlomius, FOLFOX, oxaliplatin + 5 FU + leucovorin, Bevacizumab, Avastin | University of Utah, Novartis | Colorectal Cancer | 08/15 | 08/15 | | |
|